Innovation in Stroke Care Neuravi specializes in advanced neurovascular therapies, notably their EmboTrap®II device, which is CE marked and demonstrates ongoing clinical innovation in stroke treatment, presenting opportunities to collaborate on new therapies or expand product adoption within European healthcare settings.

Strong Industry Backing The company's acquisition by Johnson & Johnson and previous collaborations with Cerenovus and Advant Medical highlight its strong industry positioning and infrastructure, facilitating potential sales through channels linked to these major healthcare entities.

Market Entry & Expansion Although currently limited to the European market with investigational status in the US, Neuravi's ongoing development and clinical focus create opportunities for partners to support regulatory approval, clinical trials, and market expansion both in the US and globally.

Funding & Growth Potential With $17 million in funding and a revenue range of up to one million dollars, Neuravi presents a growth-stage opportunity for sales of medical devices, research collaborations, or strategic partnerships aimed at scaling its innovative stroke therapy solutions.

Targeted Customer Base Focused on hospitals, stroke centers, and neurovascular clinics, Neuravi's products and research initiatives resonate with healthcare providers seeking cutting-edge treatments, making direct sales and consultative approaches highly relevant for expanding clinical adoption.